Danaher Co. (NYSE:DHR) Shares Sold by First Western Trust Bank

First Western Trust Bank trimmed its holdings in Danaher Co. (NYSE:DHRFree Report) by 3.8% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 33,787 shares of the conglomerate’s stock after selling 1,349 shares during the quarter. Danaher comprises approximately 0.4% of First Western Trust Bank’s portfolio, making the stock its 25th biggest position. First Western Trust Bank’s holdings in Danaher were worth $7,816,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. BKM Wealth Management LLC purchased a new position in shares of Danaher during the fourth quarter worth about $27,000. Wetzel Investment Advisors Inc. acquired a new stake in shares of Danaher in the fourth quarter valued at approximately $29,000. OFI Invest Asset Management acquired a new position in shares of Danaher in the 3rd quarter valued at $30,000. Rakuten Securities Inc. purchased a new stake in Danaher in the 4th quarter valued at $36,000. Finally, Financial Connections Group Inc. acquired a new stake in Danaher during the 4th quarter worth $41,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Price Performance

Shares of DHR stock traded up $1.95 during mid-day trading on Friday, reaching $253.38. The stock had a trading volume of 1,469,817 shares, compared to its average volume of 2,856,094. Danaher Co. has a 12-month low of $182.09 and a 12-month high of $259.00. The company has a current ratio of 1.85, a quick ratio of 1.51 and a debt-to-equity ratio of 0.31. The business has a 50-day simple moving average of $248.12 and a 200 day simple moving average of $233.43. The company has a market cap of $187.68 billion, a P/E ratio of 42.95, a price-to-earnings-growth ratio of 3.81 and a beta of 0.83.

Danaher (NYSE:DHRGet Free Report) last released its quarterly earnings data on Tuesday, April 23rd. The conglomerate reported $1.92 EPS for the quarter, topping the consensus estimate of $1.72 by $0.20. Danaher had a net margin of 16.78% and a return on equity of 11.43%. The business had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.62 billion. During the same period in the previous year, the firm earned $2.36 EPS. The business’s revenue for the quarter was down 2.6% compared to the same quarter last year. On average, sell-side analysts anticipate that Danaher Co. will post 7.63 earnings per share for the current year.

Danaher Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 26th. Investors of record on Friday, June 28th will be given a $0.27 dividend. The ex-dividend date is Friday, June 28th. This represents a $1.08 annualized dividend and a dividend yield of 0.43%. Danaher’s dividend payout ratio is presently 18.31%.

Insider Activity at Danaher

In other news, SVP Georgeann Couchara sold 2,622 shares of the company’s stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $242.67, for a total transaction of $636,280.74. Following the completion of the transaction, the senior vice president now owns 4,244 shares of the company’s stock, valued at approximately $1,029,891.48. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In other news, SVP Georgeann Couchara sold 2,622 shares of the company’s stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $242.67, for a total transaction of $636,280.74. Following the completion of the transaction, the senior vice president now owns 4,244 shares of the company’s stock, valued at approximately $1,029,891.48. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Rainer Blair sold 47,175 shares of the business’s stock in a transaction dated Wednesday, April 24th. The stock was sold at an average price of $249.22, for a total value of $11,756,953.50. Following the sale, the chief executive officer now owns 115,995 shares of the company’s stock, valued at approximately $28,908,273.90. The disclosure for this sale can be found here. In the last quarter, insiders sold 103,984 shares of company stock valued at $25,997,094. 10.90% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on DHR shares. Raymond James upped their target price on shares of Danaher from $240.00 to $270.00 and gave the company an “outperform” rating in a report on Wednesday, January 31st. Barclays boosted their target price on Danaher from $260.00 to $270.00 and gave the company an “equal weight” rating in a report on Wednesday, April 24th. Robert W. Baird increased their price target on Danaher from $259.00 to $271.00 and gave the stock an “outperform” rating in a report on Wednesday, April 24th. HSBC raised shares of Danaher from a “hold” rating to a “buy” rating and boosted their price objective for the company from $250.00 to $280.00 in a research note on Wednesday, April 17th. Finally, TD Cowen lifted their target price on shares of Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a report on Wednesday, April 24th. Six analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $267.31.

Get Our Latest Stock Analysis on DHR

About Danaher

(Free Report)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Featured Stories

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHRFree Report).

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.